




Belgian Cancer Registry

# CANCER FACT SHEET 2022

## PROSTATE CANCER

### ICD-10 C61



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).

**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Histopathological Grade Group:** is a grading system for prostate cancer, based on how similar the tumour is to the normal tissue (i.e., differentiation). Based on the Gleason Score, prostatic carcinomas can be divided into histopathological grade groups according to the International Society of Urological Pathology (ISUP) consensus on Gleason Grading.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE .....	5
1.1. Prostate cancer incidence: by region .....	5
1.1.1. Prostate cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022 .....	5
1.2. Prostate cancer incidence: by Histopathological Grade Group .....	6
1.2.2. Prostate cancer incidence by Histopathological Grade Group and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	6
1.3. Prostate cancer incidence: by cancer dissemination .....	7
1.3.3. Prostate cancer incidence by cancer dissemination and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
2. CANCER INCIDENCE TRENDS .....	8
2.1. Prostate cancer incidence trends: by region .....	8
2.1.1. Prostate cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....	8
2.2. Prostate cancer incidence trends: by Histopathological Grade Group .....	10
2.2.2. Prostate cancer incidence trends by Histopathological Grade Group: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards .....	10
2.3. Prostate cancer incidence trends: by cancer dissemination .....	12
2.3.3. Prostate cancer incidence trends by cancer dissemination: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards ...	12
2.4. Prostate cancer incidence trends: by age group .....	13
2.4.4. Prostate cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....	13
3. CANCER PREVALENCE .....	14
3.1. Prostate cancer prevalence: by region .....	14
3.1.1. Prostate cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022 .....	14
4. CANCER SURVIVAL .....	15
4.1. Prostate cancer survival: by region .....	15
4.1.1. Prostate cancer survival by region and age group: number at risk and net survival probabilities, 2013-2022 .....	15
4.2. Prostate cancer survival: by Histopathological Grade Group .....	17
4.2.2. Prostate cancer survival by Histopathological Grade Group: number at risk and net survival probabilities, 2013-2022 .....	17
4.3. Prostate cancer survival: by cancer dissemination .....	18
4.3.3. Prostate cancer survival by cancer dissemination: number at risk and net survival probabilities, 2013-2022 .....	18
5. CANCER SURVIVAL TRENDS .....	19
5.1. Prostate cancer survival trends: by Histopathological Grade Group .....	19

5.1.1. Prostate cancer survival trends by Histopathological Grade Group: number at risk and net survival probabilities, 2008-2022 .....	19
5.2. Prostate cancer survival trends: by cancer dissemination .....	21
5.2.2. Prostate cancer survival trends by cancer dissemination: number at risk and net survival probabilities, 2008-2022 .....	21
6. CANCER MORTALITY .....	22
6.1. Prostate cancer mortality: by region.....	22
6.1.1. Prostate cancer mortality* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021.....	22
7. CANCER MORTALITY TRENDS.....	23
7.1. Prostate cancer mortality trends: by region .....	23
7.1.1. Prostate cancer mortality* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	23



# 1. CANCER INCIDENCE



## 1.1. Prostate cancer incidence: by region

1.1.1. Prostate cancer incidence by region: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
<b>Belgium</b>	0	0	0	0	0	0	1	1	21	89	374	1,037	1,922	2,472	2,718	2,163	1,190	548	152	11	12,699	235.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[5.5]	[23.7]	[94.4]	[256.7]	[520.8]	[791.2]	[1,029.5]	[1,137.0]	[940.0]	[698.6]	[506.2]	[188.0]	[222.4]	(231.4; 239.6)
Brussels	0	0	0	0	0	0	1	0	4	14	32	87	126	153	162	124	64	41	19	1	828	220.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[0.0]	[8.7]	[32.2]	[79.2]	[250.8]	[450.7]	[722.7]	[980.6]	[1,018.6]	[792.6]	[806.0]	[876.4]	[187.6]	[137.9]	(205.3; 236.0)
Flanders	0	0	0	0	0	0	0	1	11	55	255	658	1,211	1,612	1,762	1,439	782	371	94	8	8,259	245.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[5.0]	[26.1]	[110.2]	[269.4]	[538.4]	[839.6]	[1,089.9]	[1,165.6]	[935.8]	[707.1]	[471.7]	[211.6]	[249.0]	(239.9; 250.5)
Wallonia	0	0	0	0	0	0	0	0	6	20	87	292	585	707	794	600	344	136	39	2	3,612	219.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[5.2]	[16.6]	[69.9]	[233.4]	[503.6]	[712.3]	[925.1]	[1,098.7]	[983.9]	[650.9]	[491.7]	[130.0]	[201.6]	(212.5; 227.0)

## 1.2. Prostate cancer incidence: by Histopathological Grade Group

1.2.2. Prostate cancer incidence by Histopathological Grade Group and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Histopathological Grade Group	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages	
<b>I</b>	468 [14.0]	2,031 [214.8]	830 [192.5]	3,329 [58.3]	60.8 (58.7; 62.9)
<b>II</b>	510 [15.2]	1,977 [209.1]	869 [201.5]	3,356 [58.8]	61.4 (59.3; 63.5)
<b>III</b>	248 [7.4]	1,359 [143.7]	753 [174.6]	2,360 [41.3]	43.7 (42.0; 45.5)
<b>IV</b>	138 [4.1]	799 [84.5]	618 [143.3]	1,555 [27.2]	29.3 (27.8; 30.7)
<b>V</b>	135 [4.0]	819 [86.6]	735 [170.5]	1,689 [29.6]	32.0 (30.5; 33.5)
<b>X</b>	24 [0.7]	127 [13.4]	259 [60.1]	410 [7.2]	8.3 (7.5; 9.1)

### 1.3. Prostate cancer incidence: by cancer dissemination

1.3.3. Prostate cancer incidence by cancer dissemination and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Cancer dissemination	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages	
<b>No metastasis</b>	1,347 [40.2]	6,230 [658.9]	3,312 [768.2]	10,889 [190.7]	201.2 (197.4; 205.0)
<b>Regional lymph nodes only</b>	96 [2.9]	455 [48.1]	170 [39.4]	721 [12.6]	13.2 (12.2; 14.2)
<b>Distant metastasis</b>	80 [2.4]	427 [45.2]	582 [135.0]	1,089 [19.1]	21.1 (19.9; 22.4)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Prostate cancer incidence trends: by region

2.1.1. Prostate cancer incidence trends by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
Belgium <b>N</b>	9,728	9,737	9,289	9,001	8,897	8,733	8,763	9,132	8,345	7,948	7,991	8,433	9,133	9,617	9,867	10,256	9,743	11,790	12,699				
	<b>CR</b>	191.2	190.5	180.6	173.7	170.3	165.8	165.0	170.0	154.1	145.9	146.0	153.2	164.9	172.7	176.3	182.2	172.1	207.7	222.4			
	<b>ESR2013</b>	246.2	243.2	226.5	214.9	209.2	202.0	199.8	204.8	182.9	171.3	170.1	176.8	187.6	194.4	196.2	200.5	187.2	223.1	235.5	-0.5 (-0.9; -0.2)	2004-2022	
																					-3.6 (-4.2; -2.9)	2004-2014	
																						3.4 (2.5; 4.4)	2015-2022
Brussels <b>N</b>	598	669	588	548	613	567	537	613	558	584	555	526	574	570	587	615	560	663	828				
	<b>CR</b>	124.5	138.3	120.1	110.3	121.3	109.8	101.9	113.0	100.9	104.0	97.9	91.8	99.0	97.9	100.1	103.8	93.7	110.7	137.9			
	<b>ESR2013</b>	187.3	211.4	184.1	172.1	187.7	173.5	163.4	183.7	165.4	172.3	161.2	153.3	165.9	164.8	168.2	171.7	154.7	180.1	220.7	0.0 (-0.7; 0.6)	2004-2022	
																					-1.8 (-2.8; -0.8)	2004-2016	
																						3.6 (1.4; 5.9)	2017-2022
Flanders <b>N</b>	5,931	6,141	5,961	5,986	5,873	5,765	5,715	5,939	5,490	5,027	5,125	5,447	5,930	6,258	6,496	6,701	6,608	7,805	8,259				
	<b>CR</b>	199.9	206.1	198.9	198.4	193.2	188.1	185.2	190.8	175.1	159.5	161.9	171.1	185.3	194.3	200.4	205.6	201.4	237.0	249.0			
	<b>ESR2013</b>	246.9	250.9	236.7	232.3	224.4	215.8	210.3	215.1	194.0	174.6	175.2	183.3	195.7	202.9	206.9	209.9	203.2	236.3	245.2	-0.4 (-0.8; -0.1)	2004-2022	
																					-3.6 (-4.2; -2.9)	2004-2014	



Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
																					3.6 (2.7; 4.5)	2015-2022
Wallonia <b>N</b>	3,199	2,927	2,740	2,467	2,411	2,401	2,511	2,580	2,297	2,337	2,311	2,460	2,629	2,789	2,784	2,940	2,575	3,322	3,612			
<b>CR</b>	195.0	177.6	165.4	147.9	143.7	142.2	147.7	150.5	133.1	134.7	132.7	140.6	149.6	158.1	157.3	165.6	144.5	186.2	201.6			
<b>ESR2013</b>	260.4	235.2	216.9	190.8	183.9	181.0	187.8	188.8	164.7	164.3	162.4	169.6	176.7	184.2	181.6	188.5	162.7	206.1	219.7	-0.9 (-1.5; -0.3)	2004-2022	
																					-4.4 (-5.7; -3.1)	2004-2013
																					2.8 (1.4; 4.1)	2014-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Prostate cancer incidence trends: by Histopathological Grade Group

2.2.2. Prostate cancer incidence trends by Histopathological Grade Group: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Histopathological Grade Group		2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
<b>I</b>	<b>N</b>	2,357	2,344	2,095	2,763	3,329		
	<b>CR</b>	42.1	41.6	37.0	48.7	58.3		
	<b>ESR2013</b>	46.5	45.6	39.8	51.6	60.8	-4.1 (-5.4; -2.8)	2004-2022
<b>II</b>	<b>N</b>	2,772	2,910	2,658	3,266	3,356		
	<b>CR</b>	49.5	51.7	47.0	57.5	58.8		
	<b>ESR2013</b>	53.9	55.8	50.2	60.9	61.4	3.1 (2.0; 4.3)	2004-2022
<b>III</b>	<b>N</b>	1,703	1,822	1,898	2,257	2,360		
	<b>CR</b>	30.4	32.4	33.5	39.8	41.3		
	<b>ESR2013</b>	33.7	35.4	36.5	42.4	43.7	6.9 (5.9; 8.0)	2004-2022
<b>IV</b>	<b>N</b>	1,284	1,364	1,401	1,553	1,555		
	<b>CR</b>	22.9	24.2	24.8	27.4	27.2		
	<b>ESR2013</b>	25.9	27.0	27.2	29.9	29.3	2.9 (2.0; 3.7)	2004-2022
						1.9 (0.6; 3.2)	2004-2016	
						4.8 (1.9; 7.7)	2017-2022	
<b>V</b>	<b>N</b>	1,452	1,504	1,407	1,615	1,689		
	<b>CR</b>	25.9	26.7	24.9	28.4	29.6		
	<b>ESR2013</b>	29.6	30.2	27.7	31.2	32.0	4.5 (3.5; 5.6)	2004-2022
<b>X</b>	<b>N</b>	299	312	284	336	410		
	<b>CR</b>	5.3	5.5	5.0	5.9	7.2		
	<b>ESR2013</b>	6.7	6.6	5.9	7.0	8.3	-12.5 (-14.3; -10.5)	2004-2022
						-26.0 (-31.3; -20.4)	2004-2010	

Histopathological Grade Group	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
						-15.4 (-23.0; -7.1)	2011-2014
						1.1 (-4.0; 6.4)	2015-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

### 2.3. Prostate cancer incidence trends: by cancer dissemination

2.3.3. Prostate cancer incidence trends by cancer dissemination: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Cancer dissemination		2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
No metastasis	<b>N</b>	8,455	8,745	8,185	10,078	10,889		
	<b>CR</b>	151.0	155.4	144.6	177.5	190.7		
	<b>ESR2013</b>	167.6	170.4	156.6	190.0	201.2	-1.3 (-1.7; -0.9)	2004-2022
							-4.4 (-5.1; -3.6)	2004-2014
							2.7 (1.7; 3.8)	2015-2022
Regional lymph nodes only	<b>N</b>	609	596	634	682	721		
	<b>CR</b>	10.9	10.6	11.2	12.0	12.6		
	<b>ESR2013</b>	11.8	11.5	12.1	12.8	13.2	8.1 (7.4; 8.8)	2004-2022
							9.3 (8.3; 10.4)	2004-2016
							5.7 (3.5; 7.9)	2017-2022
Distant metastasis	<b>N</b>	803	915	924	1,030	1,089		
	<b>CR</b>	14.3	16.3	16.3	18.1	19.1		
	<b>ESR2013</b>	16.8	18.7	18.5	20.3	21.1	5.5 (4.9; 6.1)	2004-2022
							1.0 (-0.9; 2.9)	2004-2010
							7.9 (7.0; 8.8)	2011-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.4. Prostate cancer incidence trends: by age group

2.4.4. Prostate cancer incidence trends by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, %	(95%CI)	Period		
<b>15-59</b>	<b>N</b>	1,467	1,584	1,504	1,476	1,560	1,377	1,355	1,439	1,316	1,234	1,138	1,174	1,260	1,299	1,288	1,286	1,159	1,437	1,523				
	<b>CR</b>	45.9	49.4	46.6	45.6	48.0	42.1	41.3	43.6	39.7	37.1	34.2	35.3	37.8	39.0	38.6	38.5	34.7	43.0	45.5				
	<b>ESR2013</b>	50.6	53.3	49.4	48.3	50.6	44.3	43.0	45.0	40.5	37.4	34.1	34.7	36.8	37.6	37.1	36.7	33.1	40.8	43.4	-1.6 (-2.2; -1.0)	2004-2022		
																					-3.6 (-4.5; -2.7)	2004-2016		
																						2.6 (0.6; 4.7)	2017-2022	
<b>60-74</b>	<b>N</b>	5,258	5,141	5,080	4,815	4,652	4,732	4,605	4,881	4,464	4,287	4,252	4,510	4,974	5,349	5,531	5,669	5,475	6,561	7,112				
	<b>CR</b>	772.7	750.5	739.5	687.9	652.8	650.7	621.3	645.7	580.3	547.3	533.7	554.9	597.4	624.4	629.1	631.0	597.1	702.1	752.2				
	<b>ESR2013</b>	767.8	746.4	739.2	694.9	667.1	665.7	637.3	665.1	595.8	561.8	549.7	572.3	614.0	640.5	641.1	641.9	608.2	712.9	765.1	-0.4 (-0.7; 0.0)	2004-2022		
																					-3.2 (-3.9; -2.5)	2004-2014		
																						3.2 (2.3; 4.2)	2015-2022	
<b>75+</b>	<b>N</b>	3,003	3,012	2,705	2,710	2,685	2,624	2,803	2,812	2,565	2,427	2,600	2,749	2,899	2,969	3,048	3,301	3,109	3,792	4,064				
	<b>CR</b>	1,024.4	995.1	861.3	831.9	797.3	759.3	791.7	778.5	694.9	645.4	678.0	702.2	734.4	752.1	767.3	816.9	751.9	911.4	942.6				
	<b>ESR2013</b>	999.5	987.0	840.1	799.9	772.9	736.5	772.3	764.5	677.0	630.2	659.8	689.4	719.0	740.8	763.3	812.9	750.4	906.5	932.0	-0.4 (-0.9; 0.0)	2004-2022		
																					-4.5 (-5.5; -3.6)	2004-2013		
																						3.8 (2.8; 4.9)	2014-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



#### 3.1. Prostate cancer prevalence: by region

3.1.1. *Prostate cancer prevalence by region: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		1-year	5-year	10-year	15-year
Belgium	<b>N</b>	12,412	48,857	78,316	100,340
	<b>CR</b>	215.4	848.0	1,359.3	1,742
	<b>ESR2013</b>	226.4	899.4	1,455.5	1,881.2
Brussels	<b>N</b>	799	2,830	4,540	5,808
	<b>CR</b>	131.4	465.3	746.4	954.9
	<b>ESR2013</b>	210.4	772.4	1,267.6	1,643.8
Flanders	<b>N</b>	8,093	32,599	52,205	67,128
	<b>CR</b>	241.4	972.4	1,557.3	2,002.4
	<b>ESR2013</b>	236.1	955.4	1,537.6	1,987.6
Wallonia	<b>N</b>	3,520	13,428	21,571	27,404
	<b>CR</b>	195.5	745.7	1,197.8	1,521.7
	<b>ESR2013</b>	210.8	814.5	1,330.6	1,714.4



### 4.1. Prostate cancer survival: by region

4.1.1. Prostate cancer survival by region and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Belgium	<b>Total</b>	97,250	99.4% (99.3%; 99.6%)	98.2% (97.9%; 98.5%)	97.6% (97.2%; 98.1%)	97.2% (95.8%; 98.6%)
	<b>15-59</b>	12,766	99.7% (99.5%; 99.9%)	98.4% (98.1%; 98.7%)	97.0% (96.5%; 97.5%)	95.1% (94.1%; 96.2%)
	<b>60-74</b>	53,585	100.0% (99.8%; 100.1%)	99.4% (99.1%; 99.6%)	99.1% (98.7%; 99.4%)	100.2% (99.3%; 101.2%)
	<b>75+</b>	30,900	98.4% (98.1%; 98.8%)	96.0% (95.3%; 96.7%)	95.4% (94.4%; 96.6%)	92.8% (88.8%; 97.0%)
Brussels	<b>Total</b>	5,986	99.0% (98.4%; 99.6%)	95.8% (94.7%; 97.0%)	92.7% (90.9%; 94.6%)	89.9% (83.7%; 96.5%)
	<b>15-59</b>	837	98.9% (98.0%; 99.8%)	96.7% (95.1%; 98.3%)	94.7% (92.5%; 96.9%)	90.0% (85.5%; 94.7%)
	<b>60-74</b>	3,192	99.7% (99.2%; 100.2%)	97.9% (96.9%; 99.0%)	95.6% (94.0%; 97.2%)	94.4% (90.7%; 98.2%)
	<b>75+</b>	1,957	97.9% (96.5%; 99.3%)	92.0% (89.2%; 95.0%)	87.4% (82.8%; 92.2%)	82.9% (67.1%; 102.4%)
Flanders	<b>Total</b>	63,574	100.0% (99.8%; 100.1%)	100.0% (99.7%; 100.4%)	100.9% (100.4%; 101.4%)	103.2% (101.5%; 105.0%)
	<b>15-59</b>	8,459	99.9% (99.7%; 100.1%)	99.2% (98.8%; 99.6%)	98.3% (97.7%; 98.9%)	97.5% (96.2%; 98.8%)
	<b>60-74</b>	34,499	100.5% (100.3%; 100.6%)	101.1% (100.8%; 101.4%)	102.1% (101.7%; 102.5%)	106.2% (105.0%; 107.5%)
	<b>75+</b>	20,617	99.2% (98.7%; 99.6%)	98.6% (97.7%; 99.4%)	100.0% (98.7%; 101.4%)	100.5% (95.6%; 105.8%)
Wallonia	<b>Total</b>	27,690	98.3% (98.0%; 98.5%)	94.4% (93.9%; 95.0%)	91.2% (90.5%; 92.0%)	85.2% (82.9%; 87.6%)
	<b>15-59</b>	3,470	99.4% (99.1%; 99.8%)	96.9% (96.1%; 97.6%)	94.5% (93.5%; 95.6%)	90.5% (88.5%; 92.6%)
	<b>60-74</b>	15,894	98.9% (98.6%; 99.2%)	95.9% (95.4%; 96.4%)	93.2% (92.5%; 93.9%)	88.4% (86.7%; 90.1%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	75+	8,326	96.6% (95.9%; 97.4%)	90.7% (89.4%; 92.1%)	86.1% (84.0%; 88.2%)	76.8% (70.1%; 84.2%)



## 4.2. Prostate cancer survival: by Histopathological Grade Group

### 4.2.2. Prostate cancer survival by Histopathological Grade Group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
Histopathological Grade Group	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	97,250	99.4% (99.3%; 99.6%)	98.8% (98.6%; 99.0%)	98.2% (97.9%; 98.5%)	97.8% (97.5%; 98.2%)	97.6% (97.2%; 98.1%)	97.2% (95.8%; 98.6%)
<b>I</b>	25,717	100.1% (99.9%; 100.3%)	100.5% (100.2%; 100.8%)	101.1% (100.6%; 101.5%)	101.9% (101.4%; 102.5%)	102.5% (101.8%; 103.2%)	106.2% (103.8%; 108.7%)
<b>II</b>	26,235	100.8% (100.7%; 101.0%)	102.0% (101.7%; 102.3%)	103.2% (102.8%; 103.6%)	104.2% (103.7%; 104.7%)	105.4% (104.8%; 106.0%)	108.2% (105.6%; 110.8%)
<b>III</b>	16,377	101.1% (100.9%; 101.4%)	102.0% (101.6%; 102.4%)	102.7% (102.1%; 103.2%)	103.2% (102.5%; 104.0%)	103.8% (102.9%; 104.7%)	106.3% (102.8%; 109.9%)
<b>IV</b>	12,296	99.5% (99.1%; 99.9%)	98.6% (98.0%; 99.2%)	97.5% (96.7%; 98.3%)	96.6% (95.6%; 97.7%)	96.1% (94.8%; 97.4%)	89.2% (84.7%; 94.0%)
<b>V</b>	13,523	96.7% (96.3%; 97.2%)	91.5% (90.8%; 92.2%)	85.6% (84.6%; 86.5%)	80.4% (79.3%; 81.6%)	76.4% (75.1%; 77.8%)	64.2% (60.9%; 67.8%)
<b>X</b>	3,110	84.3% (82.8%; 86.0%)	74.3% (72.2%; 76.4%)	66.5% (64.1%; 69.1%)	62.2% (59.4%; 65.3%)	58.5% (55.2%; 61.9%)	47.2% (40.4%; 55.3%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

### 4.3. Prostate cancer survival: by cancer dissemination

#### 4.3.3. Prostate cancer survival by cancer dissemination: number at risk and net survival probabilities, 2013-2022

Cancer dissemination	Net Survival Probability, 2013-2022						
	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	97,250	99.4% (99.3%; 99.6%)	98.8% (98.6%; 99.0%)	98.2% (97.9%; 98.5%)	97.8% (97.5%; 98.2%)	97.6% (97.2%; 98.1%)	97.2% (95.8%; 98.6%)
<b>No metastasis</b>	84,017	100.4% (100.3%; 100.6%)	101.1% (100.9%; 101.3%)	101.6% (101.4%; 101.9%)	102.1% (101.8%; 102.4%)	102.6% (102.2%; 103.0%)	104.0% (102.5%; 105.5%)
<b>Regional lymph nodes only</b>	5,366	100.4% (99.9%; 100.9%)	99.9% (99.2%; 100.7%)	97.7% (96.6%; 98.8%)	96.6% (95.2%; 97.9%)	94.9% (93.2%; 96.6%)	88.0% (82.8%; 93.5%)
<b>Distant metastasis</b>	7,871	87.9% (87.0%; 88.8%)	73.8% (72.6%; 75.1%)	61.7% (60.3%; 63.2%)	52.1% (50.5%; 53.8%)	45.5% (43.7%; 47.4%)	23.7% (20.3%; 27.8%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

## 5. CANCER SURVIVAL TRENDS



### 5.1. Prostate cancer survival trends: by Histopathological Grade Group

5.1.1. Prostate cancer survival trends by Histopathological Grade Group: number at risk and net survival probabilities, 2008-2022

Period	Histopathological Grade Group	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	<b>Total</b>	43,744	98.6% (98.4%; 98.8%)	96.4% (96.0%; 96.8%)	95.0% (94.4%; 95.5%)
	<b>I</b>	17,250	99.7% (99.5%; 100.0%)	100.2% (99.7%; 100.7%)	101.2% (100.5%; 102.0%)
	<b>II</b>	10,221	100.3% (100.0%; 100.7%)	100.8% (100.1%; 101.5%)	101.7% (100.8%; 102.7%)
	<b>III</b>	4,551	99.7% (99.1%; 100.3%)	99.4% (98.3%; 100.5%)	96.0% (94.3%; 97.7%)
	<b>IV</b>	4,472	98.0% (97.3%; 98.8%)	93.0% (91.6%; 94.4%)	88.6% (86.6%; 90.5%)
	<b>V</b>	4,164	94.2% (93.2%; 95.2%)	79.5% (77.8%; 81.3%)	69.4% (67.3%; 71.6%)
	<b>X</b>	3,086	91.2% (89.9%; 92.5%)	83.8% (81.9%; 85.8%)	80.0% (77.6%; 82.5%)
2013-2017	<b>Total</b>	43,008	98.9% (98.7%; 99.1%)	96.9% (96.5%; 97.3%)	95.9% (95.4%; 96.5%)
	<b>I</b>	12,863	99.6% (99.3%; 100.0%)	100.1% (99.5%; 100.7%)	101.2% (100.3%; 102.1%)
	<b>II</b>	11,305	100.6% (100.3%; 100.9%)	102.8% (102.3%; 103.3%)	104.6% (103.8%; 105.5%)
	<b>III</b>	6,347	100.8% (100.4%; 101.2%)	101.1% (100.2%; 102.0%)	101.7% (100.4%; 102.9%)
	<b>IV</b>	5,153	98.9% (98.2%; 99.5%)	95.4% (94.2%; 96.6%)	93.4% (91.7%; 95.1%)
	<b>V</b>	5,868	95.6% (94.8%; 96.4%)	82.1% (80.7%; 83.6%)	72.2% (70.4%; 74.1%)
	<b>X</b>	1,475	85.7% (83.5%; 87.9%)	68.5% (65.3%; 71.9%)	61.3% (57.3%; 65.6%)
2018-2022	<b>Total</b>	54,246	99.8% (99.6%; 100.0%)	99.4% (99.0%; 99.7%)	99.6% (99.0%; 100.3%)
	<b>I</b>	12,854	100.6% (100.3%; 100.9%)	102.1% (101.5%; 102.7%)	104.6% (103.5%; 105.7%)

Period	Histopathological Grade Group	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	<b>II</b>	14,930	101.0% (100.8%; 101.3%)	103.5% (103.0%; 104.0%)	106.2% (105.3%; 107.2%)
	<b>III</b>	10,030	101.3% (101.0%; 101.6%)	103.8% (103.1%; 104.5%)	106.0% (104.7%; 107.4%)
	<b>IV</b>	7,143	100.0% (99.5%; 100.5%)	99.3% (98.2%; 100.3%)	98.6% (96.6%; 100.6%)
	<b>V</b>	7,655	97.6% (97.0%; 98.2%)	88.6% (87.4%; 89.9%)	81.1% (79.0%; 83.3%)
	<b>X</b>	1,635	83.1% (80.9%; 85.5%)	64.7% (61.1%; 68.6%)	53.6% (47.8%; 60.2%)

## 5.2. Prostate cancer survival trends: by cancer dissemination

### 5.2.2. Prostate cancer survival trends by cancer dissemination: number at risk and net survival probabilities, 2008-2022

Period	Cancer dissemination	Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
<b>2008-2012</b>	<b>Total</b>	43,744	98.6% (98.4%; 98.8%)	96.4% (96.0%; 96.8%)	95.0% (94.4%; 95.5%)
	<b>No metastasis</b>	40,479	99.3% (99.1%; 99.5%)	98.7% (98.3%; 99.1%)	98.0% (97.5%; 98.6%)
	<b>Regional lymph nodes only</b>	1,326	99.5% (98.4%; 100.5%)	92.2% (89.9%; 94.5%)	86.4% (83.4%; 89.4%)
	<b>Distant metastasis</b>	1,939	82.1% (80.2%; 84.1%)	51.8% (49.1%; 54.6%)	37.2% (34.4%; 40.1%)
<b>2013-2017</b>	<b>Total</b>	43,008	98.9% (98.7%; 99.1%)	96.9% (96.5%; 97.3%)	95.9% (95.4%; 96.5%)
	<b>No metastasis</b>	37,762	99.9% (99.8%; 100.1%)	100.2% (99.8%; 100.5%)	100.6% (100.1%; 101.2%)
	<b>Regional lymph nodes only</b>	2,132	100.1% (99.4%; 100.9%)	95.4% (93.8%; 97.2%)	92.1% (89.8%; 94.5%)
	<b>Distant metastasis</b>	3,114	85.9% (84.4%; 87.4%)	58.0% (55.9%; 60.2%)	41.7% (39.4%; 44.1%)
<b>2018-2022</b>	<b>Total</b>	54,246	99.8% (99.6%; 100.0%)	99.4% (99.0%; 99.7%)	99.6% (99.0%; 100.3%)
	<b>No metastasis</b>	46,257	100.9% (100.7%; 101.0%)	103.0% (102.6%; 103.3%)	104.8% (104.2%; 105.5%)
	<b>Regional lymph nodes only</b>	3,234	100.6% (100.0%; 101.2%)	99.4% (98.0%; 100.8%)	97.8% (95.3%; 100.2%)
	<b>Distant metastasis</b>	4,757	89.2% (88.0%; 90.3%)	64.5% (62.6%; 66.5%)	49.5% (46.7%; 52.4%)

## 6. CANCER MORTALITY



### 6.1. Prostate cancer mortality: by region

6.1.1. Prostate cancer mortality\* by region: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
<b>Belgium</b>	0	0	0	0	0	0	0	0	0	0	8	22	42	88	142	255	296	362	232	48	1,495	32.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.0]	[5.5]	[11.6]	[28.7]	[53.6]	[146.4]	[226.5]	[466.0]	[826.4]	[880.1]	[26.3]	(30.7; 34.0)
Brussels	0	0	0	0	0	0	0	0	0	0	3	1	1	7	10	16	16	17	13	5	89	28.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[7.5]	[2.9]	[3.7]	[33.7]	[59.9]	[139.2]	[189.3]	[336.4]	[597.7]	[1,070.7]	[14.9]	(22.1; 34.0)
Flanders	0	0	0	0	0	0	0	0	0	0	3	10	23	52	79	157	197	260	148	32	961	31.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.3]	[4.1]	[10.4]	[27.7]	[48.8]	[137.5]	[228.4]	[502.9]	[807.7]	[893.6]	[29.2]	(29.9; 34.0)
Wallonia	0	0	0	0	0	0	0	0	0	0	2	11	18	29	53	82	83	85	71	11	445	34.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.6]	[8.8]	[15.7]	[29.6]	[61.3]	[169.0]	[230.9]	[406.0]	[937.0]	[782.4]	[24.9]	(30.7; 37.3)

## 7. CANCER MORTALITY TRENDS



### 7.1. Prostate cancer mortality trends: by region

7.1.1. Prostate cancer mortality\* trends by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	1,378	1,522	1,425	1,380	1,431	1,407	1,515	1,508	1,394	1,455	1,430	1,532	1,529	1,572	1,598	1,576	1,580	1,495		
	<b>CR</b>	27.1	29.8	27.7	26.6	27.4	26.7	28.5	28.1	25.7	26.7	26.1	27.8	27.6	28.2	28.5	28.0	27.9	26.3		
	<b>ESR2013</b>	48.2	51.1	46.3	44.1	43.3	41.0	43.6	41.6	37.4	37.9	36.3	38.4	36.9	36.7	36.2	35.1	34.3	32.3	-2.2 (-2.6; -1.9)	2004-2021
Brussels	<b>N</b>	110	117	132	103	123	104	127	125	110	104	124	113	127	123	121	126	120	89		
	<b>CR</b>	22.9	24.2	27.0	20.7	24.3	20.1	24.1	23.0	19.9	18.5	21.9	19.7	21.9	21.1	20.6	21.3	20.1	14.9		
	<b>ESR2013</b>	42.1	42.5	47.7	37.8	43.8	37.1	41.8	42.0	38.5	33.9	41.1	35.6	41.8	38.5	38.3	39.6	37.2	28.0	-1.3 (-2.2; -0.4)	2004-2021
Flanders	<b>N</b>	808	903	862	872	833	860	917	927	863	914	878	948	925	1,000	1,028	966	1,009	961		
	<b>CR</b>	27.2	30.3	28.8	28.9	27.4	28.1	29.7	29.8	27.5	29.0	27.7	29.8	28.9	31.0	31.7	29.6	30.8	29.2		
	<b>ESR2013</b>	46.7	51.2	45.9	45.4	41.9	40.9	43.3	41.7	36.5	38.3	35.1	37.4	34.7	36.5	36.3	33.5	34.0	31.9	-2.3 (-2.8; -1.9)	2004-2021
Wallonia	<b>N</b>	460	502	431	405	475	443	471	456	421	437	428	471	477	449	449	484	451	445		
	<b>CR</b>	28.0	30.5	26.0	24.3	28.3	26.2	27.7	26.6	24.4	25.2	24.6	26.9	27.2	25.4	25.4	27.3	25.3	24.9		
	<b>ESR2013</b>	53.1	53.7	47.0	43.8	45.7	42.4	45.4	41.5	38.9	38.0	37.5	41.8	40.0	37.0	35.3	37.5	33.9	34.0	-2.3 (-2.8; -1.8)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024